Assessment of bone remodelling in childhood-onset systemic lupus erythematosus

Rheumatology

Volumn 50, Issue 3, 2011, Pages 611-619

  Baker LePain, Julie C ^a   Nakamura, Mary C ^a,b   Shepherd, John ^a   von Scheven, Emily ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone turnover; Children; Cytokines; Interferon; Systemic lupus erythematosus

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; AZATHIOPRINE; BETA INTERFERON; CALCIFEDIOL; COLECALCIFEROL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BONE AGE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CHILD; DISEASE ACTIVITY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SHORT STATURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGE OF ONSET; BODY MASS INDEX; BONE REMODELING; CHILD; FEMALE; HUMANS; INTERFERON-BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 79952022188     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq307     Document Type: Article

References (43)

1. Cassone R, Falcone A, Rossi F et al. Unilateral destructive wrist synovitis in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:637-42.
2. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:839.
3. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007;119(Suppl. 2):S166-74.
4. Nissel R, Lindberg A, Mehls O, Haffner D. Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab 2008;93:1359.
5. White PH. Growth abnormalities in children with juvenile rheumatoid arthritis. Clin Orthop Relat Res 1990;259: 46-50.
6. Zemel BS, Kawchak DA, Ohene-Frempong K, Schall JI, Stallings VA. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res 2007;61:607-13.
7. Viswanathan A, Sylvester FA. Chronic pediatric inflammatory diseases: effects on bone. Rev Endocr Metab Disord 2008;9:107-22.
8. Lilleby V. Bone status in juvenile systemic lupus erythematosus. Lupus 2007;16:580-6.
9. Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M. Osteoporosis in juvenile idiopathic arthritis-a practical approach to diagnosis and therapy. Eur J Pediatr 2007;166:775-84.
10. Bacon MC, White PH, Raiten DJ et al. Nutritional status and growth in juvenile rheumatoid arthritis. Semin Arthritis Rheum 1990;20:97-106.
11. Compeyrot-Lacassagnes TP, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007;56: 1966-73.
12. Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52: 2044-50.
13. Alsufyani KA, Ortiz-Alvarez O, Cabral DA et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005;32:729-33.
14. Lilleby V, Lien G, Frey FK, Haugen M, Flato B, Forre O. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum 2005;52:2051-9.
15. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998;18:45-9.
16. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:26100-15.
17. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erhythematosus blood. J Exp Med 2003;197:711-23.
18. Ronnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003;5: 68-75.
19. Coelho LF, Magno de Freitas AG, Mennechet FJ, Blangy A, Uze G. Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci USA 2005;102:11917-22.
20. Takayanagi H, Kim S, Matsuo K et al. RANKL maintains bone homeostasis through c-fos-dependent induction of interferon-beta. Nature 2002;416:744-9.
21. Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005;208:181-93.
22. Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. J Pediatr 2003;143:402-5.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992;35: 630-40.
24. Anderson M. Use of the greulich-pyle "atlas of skeletal development of the hand and wrist" in a clinical context. Am J Phys Anthropol 1971;35:347-52.
25. Kalkwarf HJ, Zemel BS, Gilsanz V et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 2007;92:2087-99.
26. Cahue S, Sharma L, Dunlop D et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007;15:819-23.
27. Mazzuca SA, Poole AR, Brandt KD, Katz BP, Lane KA, Lobanok T. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 2006;33:1147-51.
28. Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998;25:277-84.
29. CDC. http://www.cdc.gov/GROWTHcharts/ (June 2010, date last accessed).
30. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000;15: 1477-88.
31. Rosen HN, Dresner-Pollak R, Moses AC et al. Specificity of urinary excretion of cross-linked n-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994;54:26-9.
32. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993;36:1726-34.
33. Kalla AA, Meyers OL, Kotze TJ, Laubscher R. Corticosteroid therapy and bone mass - comparison of rheumatoid arthritis and systemic lupus erythematosus. S Afr Med J 1994;84:404-9.
34. Kipen Y, Briganti E, Strauss B, Will R, Littlejohn G, Morand E. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol 1999;26:310-7.
35. Sinigaglia L, Varenna M, Binelli L et al. Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 1999;26:1280-4.
36. Swolin-Eide D, Magnusson P, Hansson S. Bone mass, biochemical markers and growth in children with chronic kidney disease: a 1-year prospective study. Acta Paediatr 2007;96:720-5.
37. Jurimae J, Pomerants T, Tillmann V, Jurimae T. Bone metabolism markers and ghrelin in boys at different stages of sexual maturity. Acta Paediatr 2009;98:892-6.
38. Gur A, Dikici B, Nas K, Bosnak M, Haspolat K, Sarac AJ. Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? BMC Gastroenterol 2005;5:30.
39. Radwanski E, Perentesis G, Jacobs S et al. Pharmacokinetics of interferon alpha-2b in healthy human volunteers. J Clin Pharmacol 1987;27:432-5.
40. Chen CJ, Chao TY, Janckila AJ, Cheng SN, Ku CH, Chu DM. Evaluation of the activity of tartrate-resistance acid phosphatase isoform 5b in normal chinese children - a novel marker for bone growth. J Pediatr Endocrinol Metab 2005;18:55-62.
41. Cole DE, Carpenter TO, Gundberg CM. Serum osteocalcin concentrations in children with metabolic bone disease. J Pediatr 1985;106:770-6.
42. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-45.
43. Lamp EC, Drexler HG. Biology of tartrate-resistant acid phosphatase. Leuk Lymphoma 2000;39:477-84.